Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology for the Development and Commercialization of CLN-081 in Greater China

December 29, 2020 Auto Bot Biosimilars, Commercialization, Development, Exclusive License Agreement, Greater China, Signs, Zai Lab 0

Shots:

  • Cullinan will receive $20M up front and is eligible to receive ~$211M in development, regulatory and sales-based milestone payments
  • Cullinan is also eligible for high-single-digit to low-teen tiered royalties based on sales of CLN-081 in Greater China includes Hong Kong, Macau and Taiwan
  • CLN-081 is an orally available, small-molecule, irreversible EGFR inhibitor, which is currently in P-I/IIa dose escalation and expansion trial for NSCLC patients

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Business Wire

The post Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology for the Development and Commercialization of CLN-081 in Greater China first appeared on PharmaShots.